Hypertension is frequently associated with obesity and natriuretic peptide levels are reported to decrease in obese subjects. Both the lower brain natriuretic peptide (BNP) concentration and insulin resistance are suggested to be associated with hypertension. However, their involvement in obesity-related hypertension has not been clearly defined. Forty-four obese women (21 normotensive and 23 hypertensive) and 25 healthy women matched for age were included in the study. Anthropometrical parameters were determined. Serum BNP, fasting insulin and glucose concentrations, and lipid parameters were evaluated. Insulin resistance was calculated using Homeostasis Model Assessment (HOMA) and Quantative Insulin Sensitivity Check Index (QUICKI) formulations. Within the obese groups, HOMA and QUICKI reflected the increased insulin resistance in hypertensive obese subjects with a significant correlation to blood pressure. The decrease in BNP in the obese groups was in favour of the hypertensive obese subjects (31.4376.43; 26.3674.29; and 17.5173.08 pg/ ml, respectively) with a fractional statistical significance between the hypertensive obese group and the controls (P ¼ 0.047). Only for the obese hypertensive group, fasting glucose, HOMA and QUICKI were significantly correlated with BNP. Moreover, fasting plasma glucose (R 2 ¼ 0.22, P ¼ 0.007) and fasting plasma insulin (R 2 ¼ 0.39, P ¼ 0.03) were independently correlated with BNP only for the obese hypertensive group. It can be concluded that the decrease in BNP concentrations in the obese hypertensive subjects seem to be well correlated with the insulin resistance.
Introduction
Brain natriuretic peptides (BNPs), in a fashion similar to atrial natriuretic peptides (ANPs), give rise to arteriolar and venous dilatation and decrease renal sodium reabsorption as a response to left ventricular wall tension or increased plasma volume. [1] [2] [3] In several studies, plasma ANP and BNP concentrations have been found to be decreased in obese subjects. [4] [5] [6] [7] Additionally, an increase in natriuretic peptides (NPs) has been reported to parallel an increase in blood pressure. 8 Either by boosting the sympathetic activity, increasing sodium and water reabsorption or upregulating the angiotensinogen type 1 receptors, insulin resistance can lead to the inextricable component of obesity and hypertension. 9 The aim of this study is to evaluate the correlations between BNP, insulin resistance and blood pressure in the obese subjects.
Materials and methods
The study was approved by the Ethics Committee of Inonu University, Faculty of Medicine and all of the participants gave written informed consent. Fortyfour obese women (as the study group) and 25 healthy lean women (as the control group) who attended the Endocrinology Outpatient Clinic of Inonu University, Faculty of Medicine from January 2005 till January 2006 were enrolled into the study.
In an attempt to avoid the influence of gender, only women were selected. The patients with a history of chronic cardiac, renal, pulmonary or hepatic parenchymal diseases, patients with a history of thyroid problems and patients using antihypertensives or diuretics were excluded. Smoking status was also noted. Each patient underwent a general physical examination, including the measurement of the height (in nearest cm, without shoes), the body weight (in nearest kg, without coats), the waist circumference (WC; the minimum circumference measured between the iliac crest and the lateral costal margin, in cm) and the hip circumference (HC; the maximum circumference over the hips, in cm). The body mass index (BMI; in kg/m 2 ) was calculated as the body weight divided by the height squared. The waist-to-hip ratio (WHR) was defined as the WC divided by the HC. The blood pressure was measured with the patient in the sitting position, using a random sphygmomanometer with small (9 Â 18 cm), medium (12 Â 23 cm) or large (15 Â 33 cm) cuffs used as appropriate. Systolic blood pressure (Korotkoff phase I; SBP) and diastolic blood pressure (Korotkoff phase V; DBP) was measured twice on the left upper arm and the average was noted. The measurement was repeated on a second visit in the same week. In case the high blood pressure persisted, the patient was noted to be hypertensive and was included in the study. Hypertension was defined in accordance with the JNC7 (Joint National Committee 7) criterion as SBP X140 mm Hg or DBP X90 mm Hg. 10 The serum samples were drawn between 0800 and 0900, after an overnight fast of 12-14 h. Serum glucose, triglycerides, total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol and very-low-density lipoprotein-cholesterol were analyzed using an autoanalyzer (Olympus Diagnostica GmbH, Lismeehan, O'Callaghan's Mills Co., Clare, Ireland). Serum insulin levels were analyzed using the chemiluminescent enzyme immunoassay technique (Immulite 2000; Diagnostic Products Corporation, Los Angeles, CA, USA). Serum BNP values were determined using the microparticle enzyme immunoassay technique (AxSYM; Axis-Shield Diagnostics Ltd, UK).
Insulin resistance was calculated using the 'Homeostasis Model Assessment' formula [HO-MA ¼ fasting plasma glucose (FPG) Â fasting plasma insulin (FPI)/22.5]. 11 Insulin sensitivity was calculated using the 'Quantative Insulin Sensitivity Check Index' formula (QUICKI ¼ 1/[log (I 0 ) þ log (G 0 )]). 12 
Statistical analysis
Statistical analysis was performed using the SPSS for Windows software package (version 13.0, SPSS Inc., Chicago, IL, USA). The Shapiro-Wilk test was used to verify the normality of the distribution of the continuous variables. The analysis of variance test and the least significant difference test were used to compare the data. The correlations between the study parameters were assessed using Pearson's correlation. The groups were compared using the w 2 test for smoking status. A stepwise multivariate regression analysis was performed to assess the influence of the following independent variables on serum BNP concentrations in the obese hypertensive group: plasma fasting glucose, plasma fasting insulin, WC, BMI, age and SBP/DBP. A Pp0.05 was considered to be statistically significant. The data was presented as mean7s.e.
Results
Twenty-five healthy lean women with normal blood pressure served as the control group (Group 1), whereas 21 obese women with normal blood pressure (Group 2) and 23 obese women with hypertension (Group 3) constituted the study groups. The groups were matched for age. There was no significant difference regarding the smoking status between the groups (four women in Group 1, one woman in Group 2 and two women in Group 3; P ¼ 0.44). There was no significant difference regarding the anthropometrical measurements between the obese groups (Groups 2 and 3). The anthropometrical measurements and the demographical features are documented in Table 1 .
There was an obvious decrease in serum BNP values in the obese groups in favour of the hypertensive obese group. Mean BNP value was 31.437 6.43 pg/ml in the control group, 26.3674.29 pg/ml in the normotensive obese group and 17.517 3.08 pg/ml in the hypertensive obese group. There was a marginally significant difference between the hypertensive obese group and the control group (P ¼ 0.047).
Serum total cholesterol and LDL-C concentrations were significantly higher in the hypertensive obese group as compared with the control group and the normotensive obese group. Plasma fasting insulin level and HOMA and QUICKI values were significantly different in both of the obese groups in comparison with the control group. However, HOMA and QUICKI were the only parameters that were different within the obese groups, which reflected a worsened insulin resistance in hypertensive individuals. Metabolic features of the groups are documented in Table 2 .
In the entire study group, the SBP was found to be significantly correlated with the anthropometrical measurements (P ¼ 0.0001, r ¼ 0.42 for body weight; P ¼ 0.002, r ¼ 0.36 for BMI; P ¼ 0.0001, r ¼ 0.43 for WC), the insulin resistance (P ¼ 0.0001, r ¼ 0.57 for HOMA; P ¼ 0.0001, r ¼ À0.52 for QUICKI; P ¼ 0.003, r ¼ 0.35 for insulin) and the BNP concentrations (r ¼ À0.25, P ¼ 0.03). The DBP showed similar correlations with the anthropometrical measurements (P ¼ 0.01, r ¼ 0.30 for body weight; P ¼ 0.03, r ¼ 0.26 for BMI; P ¼ 0.01, r ¼ 0.28 for WC), the insulin resistance (P ¼ 0.0001, r ¼ 0.47 for HOMA; P ¼ 0.0001, r ¼ À0.52 for QUICKI; r ¼ 0.26, P ¼ 0.02 for fasting insulin) and the BNP concentrations (r ¼ À0.26, P ¼ 0.02) as well. Despite the lack of any statistical significance, BNP was negatively correlated with both the anthropometrical measurements (P ¼ 0.10, r ¼ À0.19 for weight; P ¼ 0.22, r ¼ À0.15 for BMI; P ¼ 0.07, r ¼ À0.22 for WC; and P ¼ 0.12, r ¼ À0.19 for WHR) and the insulin resistance (P ¼ 0.94, r ¼ À0.01 for HOMA; P ¼ 0.82, r ¼ 0.02 for QUICKI; P ¼ 0.2, r ¼ À0.15 for FPI; and P ¼ 0.14, r ¼ À0.17 for FPG).
When the groups were evaluated separately, the insulin resistance parameters (HOMA, QUICKI and FPG) were found to be significantly correlated with BNP in only the obese hypertensive group (Table 3) . With a stepwise multivariate regression analysis, FPG (R 2 ¼ 0.22, P ¼ 0.007) and FPI (R 2 ¼ 0.39, P ¼ 0.03) were independently associated with BNP in these obese hypertensive subjects. Probability of F-to-enter was p0.05 and F-to-remove was X0.1. In the first step (Model 1) of the analysis while FPG was assessed as the constant and F was 6.27 with a R 2 ¼ 0.229 and P ¼ 0.021, BMI, WC, insulin, age and SBP were the excluded variables. In the second step (Model 2) while FPG and FPI were considered as constants and F was 6.53 with a R 2 ¼ 0.395, and P ¼ 0.007, BMI, WC, age and SBP were the excluded variables. The data are documented in Table 4 . The results were similar in a second regression analysis in which the DBP was used instead of the SBP. 
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Discussion
Obesity has come to recognition as a critical global healthcare issue in the last decades, through its interaction with several disorders including hypertension. Obese and overweight patients account for 40% of all hypertensive individuals. 13 A 10% loss of the body weight was reported to independently predict a 4.3/3.8 mm Hg decrease in 24-h SBP/DBP in overweight subjects. and insulin resistance 9 are two of the factors under research in relation to the pathogenesis of obesity-related hypertension. Both ANP and BNP are found to be effective on lowering blood pressure through their effects on natriuresis, sympathetic tonicity and renin-angiotensin-aldosterone system. In several studies, serum NP concentrations were found to be lower in the obese individuals as compared with the lean counterparts. [4] [5] [6] Obesity was reported to be associated with a 1.8-to 4.8-fold increase in the odds of having lower plasma NP levels. 4 Additionally, lower BNP levels were reported to show a significant negative correlation with the WC. 4 In agreement with these studies, despite the lack of statistical significance, we defined a similar relationship in this study. However, in contrast to Framingham's study, 4 serum BNP concentration was lower than the normotensive obese group in our hypertensive obese patients. In the abovementioned large-scale study, diabetes was another condition found to be in association with low plasma NP levels and the negative effects of obesity and diabetes on NP levels were reported to be additive. 4 The results of the study conducted by Das et al. 1 was comparable with those of Wang et al. such that the subjects with lower NT-proBNP levels were less likely to have hypertension. On the contrary, diabetes was found to be a lowering factor for this molecule. Although type II diabetes is the subsequent step in insulin resistance for most of the obese patients, the insulin resistance was not taken into consideration in the non-diabetic obese subjects in any of these studies. In this study, BNP was correlated with plasma fasting glucose, HOMA and QUICKI in the obese hypertensive group. However, these correlations could not be established either in the control group or in the normotensive subjects. The main difference for the obese hypertensive subjects was the significantly worsened insulin resistance. Therefore, it can be concluded that altered BNP activation might be the result of this metabolic disturbance. In a study conducted on healthy subjects, euglycemic hyperinsulinaemia was found to decrease ANP levels 16 although BNP was reported to be unaffected. 17 Insulin resistance is a sine qua non for the definition of metabolic syndrome and is commonly a presenting sign of obesity. It is suggested that through boosting the sympathetic activity, increasing renal sodium and water uptake, increasing sodium potassium adenosine phosphatase activity or upregulating the angiotensin II type 1 receptors, hyperinsulinaemia may lead to hypertension. 9 Using fasting insulin levels and two simple, yet widely accepted, indices such as HOMA and QUICKI, 11, 12 we defined the insulin resistant state of these obese individuals with a significant correlation to lower BNP concentrations. However, to our knowledge, there is not adequate data on the correlation of hyperinsulinaemia and/or insulin resistance and NPs. In this study, in an addition to the significant correlations, the parameters that appeared to affect BNP were plasma fasting insulin and glucose concentrations.
Although lower BNP concentrations were reported to be more frequent in the hypertensive subjects, Nishikimi et al. 18 reported similar ANP levels between normotensive subjects and hypertensive patients with normal myocardial geometry and slightly higher BNP levels in hypertensive patients with normal geometry, concentric remodelling and eccentric hypertrophy. In the above-mentioned study, BNP was not correlated with mean arterial pressure. Kohno et al. 19 reported higher plasma ir-BNP levels in hypertensive patients with left ventricular hypertrophy (LVH) as established on echocardiography, when compared with those without LVH. In both of these reports, myocardial hypertrophy was found to be the main factor affecting BNP. Additionally, BNP values were found to be overlapping for hypertensive and normotensive subjects in both of these studies. Regrettably, the lack of echocardiographic evaluation of the patients in this study precludes us to comment on the decreased BNP values in these hypertensive subjects. On the other hand, the high intraindividual variability of BNP was defined in several studies. 20, 21 This variability seems to preclude the assessment of its concentration in the individual patient with either hypertension or obesity and/or insulin resistance. The assessment of the changes in BNP concentration in longitudinal studies may enlight this issue. Association of BNP and insulin resistance in obesity-related hypertension S Tekes and AS Cikim
We can conclude that increased insulin resistance might influence the secretion of BNP in obese patients. The significantly higher HOMA and lower QUICKI values that are significantly correlated with BNP in the hypertensive obese group as compared with the normotensive obese group blames insulin resistance as the predominant factor to lead to lower BNP concentrations in obesity-related hypertension. Whether lower BNP is a result or a reason in this situation needs to be confirmed with further, more extensive, studies.
